SAN DIEGO, April 12, 2011 /PRNewswire/ — Aethlon Medical, Inc.
(OTCBB: AEMD) announced today that its wholly owned subsidiary
Exosome Sciences, Inc. (ESI) has validated the ability of its
Enzyme Linked Lectin Specific Assay (ELLSA) to identify the
presence of exosomes underlying the human immunodeficiency virus
(HIV), tuberculosis (TB), and various forms of cancer, including
ovarian, melanoma, breast, lymphoma, and colorectal.  In July
2010, ESI disclosed that it filed a patent relating to the
development of an assay that would allow researchers to detect
exosomes in blood and other fluids.  In addition to research
opportunities, Aethlon Medical plans to test ELLSA as a diagnostic
to quantify the therapeutic capabilities of the Aethlon
Hemopurifier® to remove immunosuppressive exosomes from the
circulatory system of those afflicted with cancer.  ESI is now
preparing a market survey that will be provided to researchers to
determine market demand and pricing for ELLSA as a research tool.
 

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

“We are grateful to those organizations that collaborated in
beta-testing the capabilities of ELLSA to detect exosomes, which
are increasingly being recognized as particles that deplete immune
cells or provide a mechanism to transport disease-enhancing factors
below the surveillance of the immune system,” stated Aethlon CEO,
Jim Joyce. “Additionally, the ESI ELLSA provides the potential for
a near-term revenue stream that complements the therapeutic
programs we are actively advancing at Aethlon Medical”

About Aethlon Medical

At Aethlon Medical, we create revolutionary devices to address
infectious disease and cancer. Our devices are designed to be novel
platform solutions that fill therapeutic voids or aid in disease
diagnosis and monitoring.

Our Hemopurifier® is the first

‘/>”/>

SOURCE